Viread label revision includes pediatric patients with chronic HBV

The FDA announced revisions to the Viread label to include use in pediatric patients aged 2 years to less than 12 years with chronic hepatitis B based on 48-week safety and efficacy data.
Investigators administered Viread (tenofovir disoproxil fumarate, Gilead) in treatment-experienced patients during two randomized trials.
Trial 144 comprised 89 pediatric patients who received between 8 mg/kg and 300 mg of tenofovir disoproxil fumarate or placebo. At week 48, 77% of treated patients had HBV DNA less than 400 copies/mL compared with 7% of controls. Additionally, alanine aminotransferase

Source link

Related posts

Bariatric Surgery in Teens May Cut Diabetic Kidney Disease Risk


Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania


MACCE, mortality, stroke in PCI less common in Crohn’s disease, ulcerative colitis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World